For more than three decades, the mammogram has been one of medicine’s most stubbornly standardized rituals: a woman reaches the eligible age, she is invited, she is imaged, and she returns on the same fixed schedule as every other woman in her country’s program, regardless of whether her lifetime risk is a fraction of the average or several times higher. That orthodoxy is now being challenged head-on in one of Europe’s most rigorous real-world experiments yet. At the 2026 RISE UP for Breast Cancer and Women’s Health Conference, whose selected abstracts were published open access in the journal Breast Cancer Research and Treatment as part of its Volume 217, researchers from the Danish Cancer Society and Copenhagen University Hospital – Herlev and Gentofte, working with the University of Cambridge’s Centre for Cancer Genetic Epidemiology, presented early outcomes and psychological data from PRSONAL, a randomized clinical trial asking two questions at once: whether a woman’s individual risk of breast cancer can safely determine how often she is screened, and whether telling her that risk does more psychological good than harm.
On paper, population screening looks like a triumph of public-health engineering, and in fairness it is: pooled analyses attribute to mammography screening a reduction in breast cancer mortality on the order of twenty percent among women invited to attend. But the price of uniformity is precision. A program calibrated for the average woman systematically over-screens those at low inherited and lifestyle risk, exposing them to years of unnecessary imaging, false-positive recalls, needle biopsies and, in the most contested corner of the debate, the diagnosis and treatment of cancers that would never have become clinically apparent — the phenomenon known as overdiagnosis. Simultaneously, it can under-serve the minority of women whose risk is several-fold above average and whose tumors, often surfacing between scheduled scans as so-called interval cancers, tend to be faster-growing and caught later. The PRSONAL team frames the dilemma exactly this way in its abstract: risk-stratified screening might improve the benefit-to-harm ratio, but the psychological consequences of risk communication and low-risk women’s acceptance of de-escalated screening have been unclear.
To answer those questions, the investigators turned Denmark’s organized national screening program into a laboratory. Women aged 50 to 67 attending routine biennial screening mammography were randomized one-to-one. The control group continued through the standard program with no risk stratification, exactly as before. The intervention group had its ten-year breast cancer risk calculated using the comprehensive CanRisk model, and around ninety days after the assessment the risk result was communicated automatically — a deliberately low-touch workflow designed to test whether risk stratification can be scaled inside a genuine public program rather than hand-delivered by genetic counselors to a boutique cohort. Low-risk women were, in principle, candidates for de-escalated screening, the trial’s central provocation. The study, supported by the Novo Nordisk Foundation and led by Line Pedersen, Janne Bigaard and colleagues at the Danish Cancer Society together with breast surgeon Henrik Flyger, clinical biochemist Stig Bojesen and their Copenhagen teams, is among the first to embed model-based risk scoring directly into routine service delivery on this scale.
The engine driving the experiment is CanRisk, a prediction tool developed over nearly two decades by Antonis Antoniou’s group at Cambridge, whose team — including biostatistician Joe Dennis — co-authored the Danish abstract. Unlike older models such as the Gail or Tyrer-Cuzick tools, which lean mainly on family history and reproductive factors, CanRisk integrates multiple independent strata of information. It ingests pedigree data to capture the influence of rare, high-penetrance variants in genes such as BRCA1, BRCA2, PALB2 and CHEK2. It folds in a polygenic risk score distilled from hundreds of common DNA variants, each contributing a tiny individual effect that sums into a measurable gradient of risk across the population. And it weighs mammographic density — the proportion of radiographically white, glandular tissue on the image, itself heritable and a potent independent risk factor — alongside lifestyle variables such as alcohol intake and body composition. The output is not a binary verdict but a continuous curve of absolute risk projected forward over ten years and beyond, from which screening intervals can, in principle, be rationally tuned: annual or even more intensive imaging with supplemental MRI for the highest-risk tail, and longer intervals for women whose combined profile puts them well below the population average.
That tuning is where the mathematics collides with human psychology, and it is where the Danish team has aimed its sharpest instruments. Risk communication is famously double-edged. A “low risk” label may deliver genuine relief and sustain engagement, or it may breed false security that erodes attendance even at reduced schedules. A “high risk” label may motivate vigilance, or generate anxiety, over-testing and a life lived under a diagnostic shadow. The PRSONAL protocol measures both sides of that ledger: early clinical outcomes such as detection and recall patterns, and psychological impact, including whether women randomized to learn their risk experience distress and whether low-risk women actually accept the offer of less frequent screening. Those answers matter because a screening policy is only as good as its adherence. If large numbers of women decline de-escalation, quietly purchase private mammograms, or disengage from the program altogether, the theoretical efficiency gains of stratification evaporate at the population level.
Denmark is not experimenting in isolation. The RISE UP session in which the PRSONAL abstract appeared grouped it with WISDOM and MyPeBS, the two giant randomized trials anchoring the global effort to replace fixed screening schedules with risk-adapted ones. WISDOM, a United States trial with an enrollment target of roughly 100,000 women, pits conventional annual mammography against screening intervals tailored to a woman’s measured risk. MyPeBS, recruiting across multiple centers in Europe and Israel with a target in the tens of thousands, randomizes women between their national standard program and a risk-based algorithm that assigns screening frequency by risk category. What distinguishes the Danish contribution is its operational realism: PRSONAL runs inside an existing, government-run biennial program, with risk computed and communicated automatically rather than through bespoke counseling, and it isolates the psychological variables that the larger outcome-focused trials will take years longer to resolve.
The stakes are anything but abstract. Breast cancer is the most commonly diagnosed cancer in women worldwide; the World Health Organization recorded around 2.3 million new cases and roughly 670,000 deaths from the disease in a single recent year. Screening remains one of the few interventions proven to bend that curve, which is why programs across high-income countries invite women every one to three years between their forties or fifties and their late sixties or seventies. But its costs are distributed unevenly: for every breast cancer death averted, thousands of women across repeated rounds experience a false-positive recall, and the fraction of screen-detected cancers judged to be overdiagnosed remains hotly disputed, with estimates ranging from under ten percent to a quarter or more depending on the methodology. A credible risk-stratified system would redirect intensity — more frequent imaging, and consideration of supplemental modalities such as magnetic resonance imaging, for the high-risk tail; longer, safer intervals for the low-risk majority — extracting more mortality benefit from the same machinery while reducing the collateral harm inflicted along the way.
Between principle and practice, however, stand substantial obstacles that the conference materials do not shy away from. Polygenic risk scores are calibrated overwhelmingly on data from women of European ancestry, and their predictive power attenuates in other populations, raising the concern that a naive global rollout of risk-based screening could widen existing health disparities rather than narrow them. The computational pipeline assumes digital mammography, density measurement, genotyping capacity and registry linkage that many health systems simply lack. There is also a governance question that PRSONAL’s design quietly foregrounds: when an algorithmically generated risk score replaces a standing national guideline as the reason a woman is, or is not, invited for imaging, the burden of proof for transparency, validation and informed consent shifts onto the algorithm, its developers and the program that deploys it. The funding disclosures attached to the Cambridge collaboration — support from the National Institute for Health and Care Research’s Biomedical Research Centre and from Cancer Research UK — underscore how deeply public research infrastructure is implicated in that trust.
The trial’s early readouts, presented at RISE UP, speak directly to that question of trust, although the field must wait for mature endpoint data that only years of follow-up can supply: cancer stage at diagnosis in the de-escalated arm, interval cancer rates among women screened less often, and long-term psychological trajectories. Those are the same endpoints being tracked by WISDOM and MyPeBS, which means the coming years should deliver a convergent, multi-continent verdict on whether risk-adapted screening can match the mortality reduction of uniform screening while improving its risk-benefit arithmetic. For the PRSONAL investigators, the nearer-term question is more intimate and arguably more decisive: what happens inside a woman’s head around day ninety, when a number derived from her DNA, her family tree and the texture of her breast tissue tells her she can safely wait years between mammograms — or that she should not.
The volume of selected abstracts published from the 2026 RISE UP conference reads, in that light, like a snapshot of a discipline pivoting on its axis. For four decades, the central questions of breast cancer screening have been questions of “when” — what age to begin, what age to stop, what interval in between — argued in guideline committees with a bluntness the underlying biology never respected. The trials now running, and the Danish experiment communicating risk automatically at population scale, recast the question as “who”: which woman, with which measured risk, owes herself which scan. If the psychological data hold and the clinical outcomes follow, the default mammogram that has defined preventive care for a generation of women may give way to something its architects could scarcely have imagined and its critics have long demanded — screening shaped not by the calendar, but by the person.
Subject of Research: Risk-stratified (personalized) breast cancer screening, including genetic risk assessment with the CanRisk model and the psychological impact of risk communication in the PRSONAL randomized clinical trial
Subject of Research: Cancer
Article Title: 2026 RISE UP for Breast Cancer and Women’s Health Conference
Article References: 2026 RISE UP for Breast Cancer and Women’s Health Conference. (2026). Breast Cancer Research and Treatment, 217(S1), Article 66. https://doi.org/10.1007/s10549-026-08000-9
Image Credits: AI Generated
DOI: 10.1007/s10549-026-08000-9
Keywords: breast cancer screening; risk-stratified screening; personalized screening; CanRisk model; polygenic risk score; PRSONAL trial; mammography; risk communication; WISDOM trial; MyPeBS trial
Cite Scienmag News
APA
MLA
Chicago
Nathaniel Bowman. (August 30, 2026). 2026 RISE UP Conference Targets Breast Cancer and Women’s Health Advances. Scienmag. https://scienmag.com/2026-rise-up-conference-targets-breast-cancer-and-womens-health-advances/
Nathaniel Bowman. “2026 RISE UP Conference Targets Breast Cancer and Women’s Health Advances.” Scienmag, 30 August 2026, https://scienmag.com/2026-rise-up-conference-targets-breast-cancer-and-womens-health-advances/. Accessed 30 August 2026.
Nathaniel Bowman. “2026 RISE UP Conference Targets Breast Cancer and Women’s Health Advances.” Scienmag. August 30, 2026. https://scienmag.com/2026-rise-up-conference-targets-breast-cancer-and-womens-health-advances/
Copy citation
Download RIS
Tags: advancements in breast cancer detectionadvances in personalized medicine for breast cancerbreast cancer research innovationsbreast cancer screening in Europebreast cancer screening personalizationchallenges to standard mammogram protocolschallenges to standardized mammographyeffects of risk-based screening on patient well-beingEuropean women’s health screening policiesimpact of personalized screening schedulesimpact of risk-based screening protocolsimplications of risk communication in cancer screeningindividualized breast cancer risk assessmentinnovative approaches to breast cancer preventionopen access breast cancer researchPRSONAL clinical trial on breast cancer screeningPRSONAL randomized clinical trialpsychological effects of breast cancer risk communicationpsychological effects of personalized cancer screeningre-evaluating mammogram schedulesreal-world experiments in women’s healthrole of genetic epidemiology in women’s health
